| 9.04 -15.81 (-63.62%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.59 |
1-year : | 30.31 |
| Resists | First : | 19.34 |
Second : | 25.95 |
| Pivot price | 21.44 |
|||
| Supports | First : | 8.64 |
Second : | 7.19 |
| MAs | MA(5) : | 19.77 |
MA(20) : | 22.18 |
| MA(100) : | 19.12 |
MA(250) : | 14.2  |
|
| MACD | MACD : | -0.8 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 42.2 |
D(3) : | 38.5 |
| RSI | RSI(14): 24.7 |
|||
| 52-week | High : | 25.95 | Low : | 4.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BIOA ] has closed below the lower bollinger band by 40.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 172% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.82 - 10.87 | 10.87 - 10.91 |
| Low: | 8.54 - 8.59 | 8.59 - 8.63 |
| Close: | 8.96 - 9.04 | 9.04 - 9.11 |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Fri, 31 Jul 2026
Monte Rosa, BioAge plunge after Novo’s setback (GLUE:NASDAQ) - Seeking Alpha
Fri, 31 Jul 2026
Why Is BioAge Labs Stock Sinking Friday? - benzinga.com
Fri, 31 Jul 2026
Why is BioAge Labs stock plunging today? - Investing.com
Thu, 30 Jul 2026
BIOAGE Labs Inc (BIOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Wed, 29 Jul 2026
BIOA|BIOAGE Labs Inc|Price:21.950|Chg%:+1.070 - TradingKey
Mon, 27 Jul 2026
BIOA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 85.2 (%) |
| Shares Short | 2,450 (K) |
| Shares Short P.Month | 1,990 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.53 |
| Profit Margin | 0 % |
| Operating Margin | -915.5 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | -26 % |
| Qtrly Rev. Growth | 91 % |
| Gross Profit (p.s.) | -1.65 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -3.77 |
| PEG Ratio | 0 |
| Price to Book value | 1.05 |
| Price to Sales | 38.93 |
| Price to Cash Flow | -4.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|